Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
JCR Pharmaceuticals Co., Ltd. ( (JP:4552) ) has issued an announcement.
JCR Pharmaceuticals reported a significant decline in its financial performance for the fiscal year ending March 31, 2025, with net sales dropping by 22.9% and a net loss of 4,759 million yen. The company is undergoing changes, including the exclusion of Mycenax Biotech Inc. from its subsidiaries and adjustments in accounting policies, as it aims to improve its financial standing and operational efficiency in the coming fiscal year.
The most recent analyst rating on (JP:4552) stock is a Buy with a Yen700.00 price target. To see the full list of analyst forecasts on JCR Pharmaceuticals Co., Ltd. stock, see the JP:4552 Stock Forecast page.
More about JCR Pharmaceuticals Co., Ltd.
JCR Pharmaceuticals Co., Ltd. operates in the pharmaceutical industry, focusing on the development and manufacturing of biopharmaceuticals. The company is listed on the Tokyo Stock Exchange and is known for its innovative treatments and products aimed at addressing rare diseases and unmet medical needs.
Average Trading Volume: 652,898
Technical Sentiment Signal: Sell
Current Market Cap: Yen58.29B
For an in-depth examination of 4552 stock, go to TipRanks’ Stock Analysis page.